首页> 外国专利> TARGETS FOR HUMAN MICRO RNAS IN AVIAN INFLUENZA VIRUS (H5N1) GENOME

TARGETS FOR HUMAN MICRO RNAS IN AVIAN INFLUENZA VIRUS (H5N1) GENOME

机译:禽流感病毒(H5N1)基因组中人类微RNA的靶标

摘要

The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In animal models, baculovirus-derived recombinant H5 vaccines were immunogenic and protective, but results in humans were disappointing even when using high doses. Currently, two classes of drugs are available with antiviral activity against influenza viruses: inhibitors of the M2 ion channel, amantadine and rimantadine, and inhibitors of neuraminidase, oseltamivir, and zanamivir. There is paucity of information regarding effectiveness of these drugs in H5N1 infection. These drugs are also well known to have side effects like neurotoxicity. Thus there exists a need to develop alternate therapy for targeting the Avian flu virus (H5N1). The present invention addresses this need in the field.
机译:本发明涉及禽流感病毒(H5N1)基因组中人microRNA的靶标,并提供针对H5N1病毒的特异性miRNA靶标。现有的禽流感治疗方法用途有限,这主要是由于病毒基因组的遗传重配,产生了新的蛋白质并因此逃避了免疫反应。在动物模型中,杆状病毒衍生的重组H5疫苗具有免疫原性和保护性,但即使使用高剂量,人类的结果也令人失望。当前,有两类对流感病毒具有抗病毒活性的药物:M2离子通道抑制剂,金刚烷胺和金刚乙胺,以及神经氨酸酶,奥司他韦和扎那米韦的抑制剂。关于这些药物在H5N1感染中有效性的信息很少。这些药物还具有副作用,如神经毒性。因此,需要开发针对禽流感病毒(H5N1)的替代疗法。本发明解决了该领域的需求。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号